Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol ii

Blood

Volumn 100, Issue 2, 2002, Pages 420-426

  Aricò, Maurizio ^{a,b,c,d,e,f,g,h}   Valsecchi, Maria Grazia ^{a,b,c,d,e,f,g,h}   Conter, Valentine ^{a,b,c,d,e,f,g,h}   Rizzari, Carmelo ^{a,b,c,d,e,f,g,h}   Pession, Andrea ^{a,b,c,d,e,f,g,h}   Messina, Chiara ^{a,b,c,d,e,f,g,h}   Barisone, Elena ^{a,b,c,d,e,f,g,h}   Poggi, Vincenzo ^{a,b,c,d,e,f,g,h}   De Rossi, Giulio ^{a,b,c,d,e,f,g,h}   Locatelli, Franco ^{a,b,c,d,e,f,g,h}   Micalizzi, Maria Concetta ^{a,b,c,d,e,f,g,h}   Basso, Giuseppe ^{a,b,c,d,e,f,g,h}   Masera, Giuseppe ^{a,b,c,d,e,f,g,h}  

^a Ospedale dei Bambini G Di Cristina   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Unit di Emato oncologia Pediatrica   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; CLINICAL PROTOCOL; CROSS RESISTANCE; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0037100416     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.2.420     Document Type: Article

References (15)

1. Uniform criteria for childhood acute lymphoblastic leukemia risk classification
2. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP-ALL 91 study: Associazione Italiana Ematologia Oncologia Pediatrica
3. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)
4. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86
5. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group
6. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL REZ BFM 85): A relapse study of the BFM group
7. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Children's Cancer Group phase III trial
8. Augmented Berlin-Frankfurt-Münster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group
9. Proposals for the classification of the acute leukemias: French-American-British Cooperative group
10. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group
11. Regression models and life-tables
12. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic Leukemia
13. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic Leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
14. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
15. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy: The Associazione Italiana di Ematologia ed Oncologia Pediatrica